The U.S. government awarded $486 million to AstraZeneca Plc to develop and secure supplies of up to 100,000 doses of Covid-19 antibody treatment, a similar class of drug that was used in treating President Donald Trump.

BioSpace reviews some of the more interesting recently published scientific studies, including whether the Covid-19 virus relieve pain.

The U.S. National Institutes of Health is launching a clinical trial of a combination of Gilead Sciences’ antiviral drug remdesivir (Vitrakvy) and hyperimmune intravenous immunoglobulin (hIVIG).

Cytokinetics’ stocks plummeted after the company released topline results from a Phase III cardiovascular clinical trial with partners Amgen and Servier in which the secondary endpoint to prove potential to save lives failed. 

Pfizer’s Phase III study assessing Ibrance as a potential treatment for early breast cancer patients who have residual invasive disease following neoadjuvant chemotherapy failed to meet the clinical trial’s primary endpoint.

Swedish Orphan Biovitrum (Sobi) announced that the rare disease drug maker’s phase 3 study of avatrombopag did not meet the clinical trial’s primary endpoint, sending the company’s shares sharply down.

Corbus Pharmaceuticals intends to restructure the company’s workforce and reallocate capital toward specific clinical and preclinical programs.

Japan’s Takeda Pharmaceutical said on Friday an alliance of drugmakers the company spearheads enrolled the first patient in a global clinical trial of a blood plasma treatment for Covid-19 after months of regulatory delays.

Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19 […]

Pfizer and Opko Health reported their Phase III clinical trial of somatrogan met the primary endpoint compared to Genotropin (somatropin) for treating children 3 to 18 years of age with growth hormone deficiency (GHD).